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STUDY PROTOCOL
Feasibility, tolerance and effects of adding 
impact loading exercise to pulmonary 
rehabilitation in people with chronic obstructive 
pulmonary disease: study protocol for a pilot 
randomised controlled trial
Erin Cecins1,2, Kylie Hill1,3, Dennis R. Taaffe1,4,5, David Manners6, Anne‑Marie Hill1, Robert U. Newton4,5,7, 
Daniel A. Galvão4,5 and Vinicius Cavalheri1,3,8*  
Abstract 
Background: Chronic obstructive pulmonary disease (COPD) is a disorder linked with a multitude of extra pulmo‑
nary manifestations (also known as treatable traits), including low bone mineral density (BMD). To date, no specific 
guidelines exist for the management of BMD in this population. Impact loading exercise has been identified as an 
intervention that improves or maintains BMD in other populations. However, the feasibility of and tolerance to impact 
loading exercise has not been tested in people with COPD. The aim of the proposed study will be to investigate the 
feasibility and tolerance of adding impact loading exercise to a standard pulmonary rehabilitation programme (PRP) 
in people with COPD and report its effects on bone health, balance and falls risk.
Methods: This is a protocol for a pilot feasibility and tolerance randomised controlled trial (RCT). Fifty‑eight people 
with COPD will be randomly allocated, on a 1:1 ratio, to either the experimental or control group. Initially, participants 
in both groups will complete a standard 8‑week (twice‑weekly) PRP followed by a 32‑week period of maintenance 
exercises. Over the initial 8‑week period, participants allocated to the experimental group will also undertake targeted 
lower limb resistance exercises and commence a programme of impact loading exercises (e.g. bounding and drop 
jumps). On completion of the initial 8‑week PRP, in addition to the standard maintenance exercises, participants in 
the experimental group will continue with home‑based impact loading exercises, four times a week, for the extra 
32 weeks. The primary outcome of this study is feasibility of and tolerance to impact loading exercises. Feasibility will 
be measured using data collected pertaining to recruitment, withdrawal and completion. Adherence to the exercises 
will be collected using exercise logs. Tolerance to the exercises will be determined using outcomes to assess pain, 
recording any adverse effects such as a fall and feedback from the participants in semi‑structured interviews on com‑
pleting of the trial. The effects of the 40‑week experimental intervention on bone health, balance and falls risk will be 
reported.
Discussion: This pilot RCT will test the feasibility and tolerance of an intervention that has never been trialed in peo‑
ple with COPD. It will also provide initial information regarding the size of the effect this intervention has on outcomes 
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Background
Chronic obstructive pulmonary disease (COPD) of 
moderate severity affects 1 in 10 adults over the age of 
40  years and is projected to be the third leading cause 
of death globally by 2030 [1]. This disease is character-
ised by airflow limitation that is not fully reversible and 
results in persistent respiratory symptoms such as dysp-
nea [2]. However, it is now accepted that COPD is a sys-
temic condition with several important comorbidities 
and extrapulmonary manifestations [2]. Of note, people 
with COPD die with their disease, not from their disease 
and comorbidities, and extrapulmonary manifestations 
are known to impact prognosis [3]. Optimal management 
of these comorbidities and extrapulmonary manifesta-
tions is now, in the era of precision medicine, recognised 
as a priority in the national and international guide-
lines for care of people with this condition [2, 4]. More 
recently, comorbidities and extrapulmonary manifesta-
tions in people with COPD have been badged as “treat-
able traits” [5].
Earlier work on the management of treatable traits in 
people with COPD has focused on interventions to ame-
liorate skeletal muscle dysfunction, obesity and anxi-
ety and depression [6–8]. However, there has been little 
focus on the prevention of bone mineral density (BMD) 
loss in this population. Of note, people with COPD have 
greater loss of BMD when compared with the general 
population, as previous work has reported that as many 
as 70% of people with severe COPD have evidence of 
osteoporosis [9, 10]. This is considerably greater than the 
estimated prevalence in Australian adults aged ≥ 50 years 
of 9.4% (95% confidence interval [CI] 8.7 to 10.1%) [11]. 
This increased prevalence is concordant with the constel-
lation of risk factors for loss of BMD that are frequently 
observed in people with COPD namely, older age, sed-
entary lifestyle, prolonged smoking history, low fat-free 
mass, prolonged use of inhaled corticosteroids and fre-
quent short-term use of oral corticosteroids [12, 13].
Low BMD and osteoporosis in people with COPD 
are of great concern as this population has deficits in 
balance, which are likely to increase their falls risk. For 
instance, the prevalence of falls reported in people with 
COPD over a 12-month period (40%) is higher than 
the prevalence of falls over the same time period in 
community-dwelling older adults (29 to 33%) [14–16]. 
A study in a large cohort of elderly women (n = 4050) 
found that, second to osteoarthritis, the highest num-
ber of falls was associated with a diagnosis of COPD 
[17]. Loss of BMD increases the likelihood of fractures 
as a consequence of a fall (i.e. minimal trauma frac-
tures), which in people with COPD can be catastrophic. 
Specifically, a previous population-based cohort study 
that included 11,985 participants (771 of whom had a 
diagnosis of COPD) demonstrated that 1-year rela-
tive risk (RR) for mortality following hip fractures 
was 71% higher in people with COPD than in those 
without COPD (RR [95% CI] 1.71 [1.55 to 1.88]) [18]. 
The increased prevalence of low BMD in people with 
COPD, coupled with their increased risk of falls and 
mortality following hip fractures, creates an urgent 
need to explore strategies that may enhance BMD or 
prevent further loss of BMD in this population [19].
Management and prevention of BMD loss in the adult 
population consists of pharmacological interventions 
(e.g. bisphosphonates) and lifestyle modification such 
as increased participation in physical activity, smoking 
cessation, limiting alcohol intake to ≤ 2 units/day and 
ensuring adequate dietary calcium intake and vitamin 
D [20]. Recent national guidelines for the prevention 
and management of osteoporosis recommend that, in 
order to reduce the risk of falls and rate of injurious falls, 
older adults should engage in high to very high intensity 
resistance training, moderate to high intensity impact 
loading exercise and balance training [21, 22]. Pulmo-
nary rehabilitation is recommended as part of standard 
management for individuals with COPD [23]. Generally, 
pulmonary rehabilitation programmes (PRPs) consist of 
supervised exercise training, disease-specific education, 
self-management strategies and psychosocial support 
[23]. There is robust evidence showing the positive effect 
PRPs have on health-related quality of life (HRQoL), 
symptom management and exercise tolerance [23, 24]. 
To date, current national and international guidelines for 
PRPs do not include recommendations for impact load-
ing exercise or balance training. The exercise training 
programme included in PRPs across Australia focusses 
on aerobic exercises, such as ground-based walking and 
some functional resistance exercises [25]. Although the 
effect of such exercise training on BMD in people with 
COPD is unknown, it is likely to have little if any effect 
because, during walking, the ground reaction forces 
resulting from the lack of a flight phase (which would be 
such as BMD, balance and falls risk. These data will be critical when designing a definitive RCT to advance this area of 
research.
Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTR): 12620 00108 5965 (20/10/2020)
Keywords: COPD, Bone health, Impact loading, Treatable traits
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seen in running/jumping tasks) is insufficient to produce 
an osteogenic effect [26].
Studies in adults and older adults have suggested that 
impact loading exercises are safe and osteogenic [27, 28]. 
In fact, impact loading exercise has recently been tested 
in older men with prostate cancer undergoing andro-
gen deprivation therapy, who have a high prevalence of 
comorbidities [29, 30]. The results from these interven-
tions indicate that impact loading and resistance exer-
cise can be safely undertaken in older men with prostate 
cancer and helps preserve spine and hip BMD as well 
as enhancing overall musculoskeletal function [29, 30]. 
There is a need to explore the effect on BMD of adding 




The aims of this study are, in people with COPD:
1. To examine the feasibility of and tolerance to adding 
impact loading exercise to a standard PRP.
2. To report the effects of adding impact loading exer-
cise to a standard PRP on bone health, balance and 
falls risk.
Study design and participants
This is a protocol for a pilot, parallel group, feasibility and 
tolerance randomised controlled trial (RCT). The study 
has been approved by the ethics committees at St John 
of God Midland Hospital (#1494) and Curtin University 
(HRE2020-0044), in Perth, Western Australia, and has 
been registered with the Australian and New Zealand 
Clinical Trials Registry (ANZCTR) (12620001085965, 
20/10/2020). It has been designed following the Standard 
Protocol Items: Recommendations for Interventional Tri-
als (SPIRIT) checklist [31] and will be reported in accord-
ance with the Consolidated Standards of Reporting Trials 
(CONSORT) extension for Pilot and Feasibility Trials 
statement [32]. The study flow diagram is presented in 
Fig. 1.
Patients will be deemed eligible for the study if they 
have a confirmed diagnosis of COPD [2] and have been 
referred to the PRP at St John of God Midland Hospital 
in Perth, Western Australia. People with COPD will be 
excluded if they (i) take prescription medication known 
to affect bone metabolism as the effect of the interven-
tion on BMD will be unknown; (ii) have any mobility 
deficits, significant injury or surgical intervention that 
impairs their capacity to participate in weight bear-
ing activity which is essential in order to complete the 
intervention; (iii) have any past or present evidence of a 
fragility fracture due to the risk of causing further harm; 
(iv) have any co-morbid conditions, physical or cogni-
tive impairments thought to significantly compromise 
performance during the assessments and intervention; 
and (v) are unable to understand spoken or written Eng-
lish. Note: participants enrolled in the trial that are sub-
sequently prescribed medication known to affect bone 
metabolism will continue in the trial and this information 
recorded.
Recruitment and consent
Potential participants will be identified from the referrals 
received for the St John of God Midland Hospital PRP. If 
they meet the inclusion criteria, they will be invited to 
participate in the study by the primary investigator (EC). 
After written informed consent has been obtained, par-
ticipants will complete baseline assessments and then 
be randomised into either the control or experimen-
tal group. The study intervention period will run over 
40 weeks, with three assessment time points: (i) prior to 
randomisation (i.e. at baseline), (ii) on completion of the 
8-week PRP (interim assessment) and (iii) on completion 
of the 40-week intervention period.
Randomisation and allocation concealment
Participants will be randomly allocated on a 1:1 ratio. The 
primary investigator will be blinded to this process. The 
randomisation sequence will be computer-generated and 
stratified according to any moderate or severe exacerba-
tions of COPD [2] within the past 6  months and BMD 
(i.e. T-score <  − 2.5 or T-score ≥  − 2.5) at either the spine 
or hip. The randomisation sequence will be generated 
and concealed using the Research Electronic Data Cap-
ture (REDCap) software [33].
Pulmonary rehabilitation and home‑based training 
programme (common to both groups)
The total duration of the intervention period will be 
40 weeks. Participants in both groups will complete the 
standard 8-week PRP followed by 32  weeks of main-
tenance exercises to be completed at home. The PRP is 
undertaken twice a week and is supervised by a physi-
otherapist. It comprises all the core components rec-
ommended by the international guidelines [4, 23]. 
These include an aerobic component, most commonly 
a ground-based walking programme prescribed using 
results of a 6-min walk test (6MWT), functional upper 
and lower limb resistance exercises that require minimal 
equipment so they can be replicated at home (e.g. sit to 
stands), psychosocial support and disease-specific edu-
cation which includes information on self-management 
strategies [23, 34]. Participants in the trial will receive 
group education sessions on the usual topics covered 
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in PRP (i.e. benefits of physical activity) in addition to 
education specific for the individual (i.e. smoking ces-
sation). To avoid contamination, participants in the 
experimental and control groups will attend the pulmo-
nary rehabilitation classes on different days of the week. 
After completing the first 1 or 2 weeks of the PRP, par-
ticipants in both groups will be encouraged to perform 
a home-based exercise programme. Whilst attending 
the PRP, participants will be instructed to complete this 
home programme on an additional 3 days each week, so 
that they are exercising 5 days a week (twice supervised, 
three times at home). On completion of the PRP, all par-
ticipants will be instructed to continue with the home-
based programme for 5 days per week as a maintenance 
programme. The home programme comprises a continu-
ation of the exercises completed within the PRP sessions. 
In order to maximise musculoskeletal health and func-
tion, participants in both groups will be provided with 
calcium (1000 mg/day) and vitamin D (800 IU/day) sup-
plements throughout the 40-week intervention period 
[21]. Each participant will be informed the reason why 
the supplements are being provided. Participants will be 
asked if they have previously taken or are currently tak-
ing calcium and vitamin D supplements. If they do, par-
ticipants will be asked to cease taking their supplements 
and provided with the supplements for the trial. This will 
be undertaken in consultation with their General Practi-
tioner (GP).
Experimental intervention
In addition to the standard PRP, over the initial 8-week 
period, participants allocated to the experimental 
group will also undertake additional targeted, lower 
limb resistance exercises and commence a programme 
of impact loading exercise. The resistance exercises will 
be commenced at the beginning of the 8-week PRP and 
are designed to improve gluteal, hamstring, quadriceps 
and calf muscle strength in preparation for the impact 
loading exercises. The impact loading exercise will 
commence in week 5 of the PRP and will be undertaken 
Fig. 1 RCT protocol flow diagram
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in accordance with current recommendations on exer-
cise prescription for the prevention and management 
of osteoporosis [21]. Details of the exercises including 
type, sets and repetitions are included in Table  1. The 
intensity, frequency, number of sets and repetitions of 
each impact loading exercise will be tailored taking into 
account the participant’s existing bone health status, 
co-morbidities and functional/clinical risk factors for 
falls and fractures. Each participant will be categorised 
as low, moderate or high risk for a fragility fracture and 
the prescription of the impact loading exercises will be 
modified accordingly [21]. The exercises will be modi-
fied as required, taking into account the participants 
physical capabilities and/or any reports of pain. All 
modifications to the exercises will be recorded in the 
exercise training logs.
The additional exercises will be closely supervised by 
a physiotherapist and implemented within the standard 
PRP using a circuit training approach. Those who tolerate 
the impact loading exercises well during weeks 5 and 6 of 
the PRP, with no reports of pain and no safety concerns, 
will be asked to complete an extra two sessions of home-
based impact loading exercise in weeks 7 and 8. The first 
home-based session will be supervised by a physiother-
apist. A suitable area will be established in the patient’s 
home environment to complete the exercises taking into 
account safety as well as a consistent floor surface. Par-
ticipants will also be asked to wear the same or similar 
footwear every time they complete the exercises. In those 
who describe difficulties with the impact loading exercise 
in week 6 of the PRP, such as onset of pain or intolera-
ble breathlessness, home-based training will be delayed 
until such time as they report no difficulties. Individu-
als who report issues with continence whilst performing 
the impact loading exercises will be offered a referral to 
a continence physiotherapy clinic. If difficulties during 
impact loading exercise are reported up to week 8, the 
individual’s participation in the intervention will be dis-
continued, but they will be asked to attend all remaining 
assessment sessions so their data can be analysed accord-
ing to the intention to treat principle.
Following the completion of the 8-week PRP, in addi-
tion to the standard home exercise programme, partici-
pants who tolerate the impact loading will be instructed 
to continue with home-based impact loading exercise, 
four times a week, for an extra 32 weeks. In addition to 
the home visit scheduled during the PRP, in the 32 weeks 
following completion of the PRP, a physiotherapist will 
visit the participants at home on another two occasions 
to progress the impact loading exercises (Table  1). Par-
ticipants will be given an additional exercise training log 
to track adherence and difficulties experienced with the 
impact loading programme.
Throughout the 32 weeks that follow the PRP, partici-
pants will be contacted once a fortnight by the primary 
investigator via phone to check their adherence to the 
exercises and discuss any difficulties or barriers they are 
experiencing with completing the programme, including 
any musculoskeletal issues such as pain. Throughout the 
intervention period, participants will be encouraged to 
contact the primary investigator with any adverse reac-
tions or events. Specifically, this will include any falls, 
hospitalisations for any reason or visits to their GP for 
non-routine tests or appointments. In addition, partici-
pants will be asked about their adherence to taking the 
calcium and vitamin D supplements.
Additional follow‑up in control group
Following the completion of the 8-week PRP, participants 
in the control group will be contacted every 4 weeks, via 
a phone call, for 32 weeks. During the phone calls, they 
will be encouraged to report any issues with the home-
based exercise programme and will be asked about any 
hospitalisations or visits to the GP for non-routine tests 
or appointments in the previous 4  weeks. In addition, 
participants will be asked about their adherence to taking 
the calcium and vitamin D supplements.
Outcome measures
Measures related to the primary aim (i.e. feasibility and 
tolerance) will be recorded throughout the duration 
of the study using exercise logs and scheduled contact 
points with the participants. Assessments related to the 
secondary aim and those used to evaluate the PRP will 
be performed at three time points: (i) prior to randomi-
sation (i.e. at baseline), (ii) on completion of the 8-week 
PRP (interim assessment) and (iii) on completion of the 
40-week intervention period. During these assessment 
periods, measures will be made (across two non-consec-
utive days) of BMD, body composition, balance, falls risk, 
exercise capacity, HRQoL, functional limitation resulting 
from dyspnea and feelings of anxiety and depression. In 
addition, descriptive variables including height, weight, 
age, gender, lung volumes and smoking history will be 
recorded. Specific details on the measures and assess-
ments are provided below. Body composition and BMD 
will only be measured at two time points, at baseline and 
on completion of the 40-week intervention period.
Primary outcomes
Feasibility
To assess feasibility of the study protocol, data will be 
recorded pertaining to recruitment, withdrawal and 
completion, as well as adherence to the prescribed ses-
sions (Table 2). The following cut-off points will be used 
to determine feasibility: recruitment rate of 50% (of 
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participants screened as eligible for the study) and com-
pletion rate of 70% (including all assessments and inter-
vention period). Adherence to all exercises prescribed 
during the PRP and at home will be tracked using exer-
cise logs, completed by the participant. A completion 
rate of 75% of supervised and home-based exercises will 
be considered adherent to the intervention.
Tolerance
Tolerance of the experimental intervention will be com-
pared to the standard PRP by:
1. Asking participants to rate any lower limb joint dis-
comfort/pain at the completion of each exercise 
component of the exercise programme through 
use of the visual analogue scale (VAS; 0 to 10) [35]. 
These components include the walking programme, 
upper and lower limb resistance exercises and for 
the experimental group the targeted high-intensity 
lower limb resistance and impact loading exercises. 
During the home-based sessions, participants will be 
asked to record the VAS score for pain in a workbook 
and to contact the research team for guidance if they 
experience any increase in pain. Rating of perceived 
exertion (RPE) will be recorded using the RPE scale 
and breathlessness using the modified BORG dysp-
noea scale [36].
2. Asking participants to immediately contact the pri-
mary investigator if they experience any adverse 
events, such as a fall, throughout the duration of the 
study. These data will be recorded by the primary 
investigator.
3. On study completion, feedback regarding their expe-
riences will be sought from the participants, in the 
experimental group only, through semi-structured 
interviews.
Secondary outcomes
Bone mineral density and body composition
Dual-energy X-ray absorptiometry (DXA, Lunar Prodigy) 
will be used to assess BMD (g/cm2) of the hip (total hip 
and femoral neck) and lumbar spine (L2 to L4) regions as 
well as whole body bone mineral content (BMC, g) and 
body composition. Regional and whole body lean mass 
(including appendicular skeletal muscle mass) and fat 
mass will be derived from the whole body DXA scan. The 
DXA scan will be conducted by a trained technician who 
will be blind to group allocation.
Balance
Balance will be assessed using the Berg Balance Scale 
(BBS) and the Four Square Step Test (FSST). The BBS is 
one of the most widely used clinical outcome measures 
to assess balance in older adults and has been shown to 
be sensitive to change following completion of a PRP in 
people with COPD [37, 38]. The FSST measures dynamic 
balance and is a reliable and valid measure for predicting 
falls in the elderly [39]. In addition the Activities-specific 
Balance Confidence (ABC) questionnaire will be used to 
determine participant’s confidence in performing activi-
ties without losing their balance and has good test–retest 
reliability and predictive capacity for falls in adults living 
in the community [40, 41].
Falls risk
Falls risk will be screened using the Falls Risk for Older 
People in the Community Screen (FROP-Com Screen). 
This is a 3-item falls risk screening tool that includes falls 
history in the past 12 months, functional status and bal-
ance. The score ranges between 0 and 9 and scores ≥ 4 
indicate high risk of falls [42].
Outcomes completed as part of the usual pulmonary 
rehabilitation programme
Other outcomes completed as part of the standard PRP 
will include the following: exercise capacity, measured 
using the 6-min walk test (6MWT) [43, 44]; HRQoL, 
measured using the interviewer administered version of 
the Chronic Respiratory Disease Questionnaire (CRDQ) 
[45]; functional limitation resulting from dyspnoea using 
the modified Medical Research Council Scale (mMRC) 
[46]; and anxiety and depression using the Hospital Anxi-
ety and Depression Scale (HADS) [47, 48].
Data management and analyses
Data will be entered and stored using REDCap data col-
lection tools [33]. All data from the REDCap database 
Table 2 Measures to assess feasibility of the impact loading exercise
Recruitment and completion ‑ Number of participants who were screened
‑ Number of eligible participants who were recruited (i.e. provided written consent)
‑ Number of participants who withdrew
‑ Number of participants who completed the intervention period
‑ Number of participants who completed all assessments and the intervention period
Adherence ‑ Number of supervised sessions completed
‑ Number of home‑based sessions completed
Page 8 of 10Cecins et al. Pilot Feasibility Stud           (2021) 7:151 
will be de-identified. Statistical analyses will be per-
formed using SPSS® (Statistical Package for Social Sci-
ences, version 25.0 for Windows). As this is a pilot study, 
data pertaining to the primary aims (i.e. feasibility/toler-
ance) will be reported using descriptive statistics such 
as means and standard deviations (parametric data) or 
medians and interquartile ranges (non-parametric or 
ordinal data). Categorical data will be reported as fre-
quencies and proportions. Estimates of the effect of the 
intervention on bone health, balance and falls risk will be 
determined using linear regression analysis and unstand-
ardised beta coefficients.
Sample size calculations
Justification of the sample size for pilot studies needs to 
balance issues of imprecision (small samples) against cost 
(large samples). As the primary goal of the pilot study is 
determining feasibility outcomes and not ensuring ade-
quate power to detect a small between-group difference, 
it is inappropriate to calculate the sample size required 
to detect between-group differences. For this study, jus-
tification of the sample size aligns with an approach that 
has been described by experts that utilises confidence 
intervals (CI) [49]. The sample size will be large enough 
to provide a level of precision around an estimate of the 
effect for a given outcome (e.g. between-group differ-
ence in BMD) that would indicate that a definitive RCT 
in this area is worth pursuing. Rather than the usual 
95% CI required for hypothesis testing, experts suggest 
that an 80% CI will satisfy the need for reasonable cer-
tainty for decision making based on pilot data. Using this 
approach, a sample size of 46 will allow us to comment 
on whether a standardised effect size for the change in 
BMD of 0.25 would be considered realistic in a definitive 
RCT. To account for a predicted 20% drop out rate, the 
target sample size for the study will be 58. In the previ-
ous annual report for 2017/2018, 222 people with COPD 
were referred to the pulmonary rehabilitation pro-
gramme at St John of God Midland Hospital, a significant 
increase from the 138 patients referred the year before 
(2016/217). Of these, 81 were enrolled in the programme. 
We anticipate there will be a sufficient number of refer-
rals to the programme to recruit 58 participants over a 
2-year period.
Discussion
The deterioration of bone health in people with COPD is 
of concern given that it is often undiagnosed until bone 
fractures occur. Recent studies have mainly focused 
on investigating the prevalence and risk factors for low 
BMD (i.e. osteoporosis) in people with COPD rather 
than developing strategies to ameliorate this problematic 
extrapulmonary manifestation of COPD.
This study will contribute novel information regard-
ing the non-pharmacological management of bone 
health in people with COPD referred to a PRP. This 
pilot RCT will test an intervention, aimed at attenuat-
ing loss of BMD, that has never been trialed in people 
with COPD. It will investigate whether impact load-
ing exercise, as a non-pharmacological intervention, 
is feasible and well-tolerated by this population. The 
pilot RCT will also provide initial information regard-
ing the size of the effect this intervention has on out-
comes such as BMD, balance and falls risk. These data 
are critical when designing a definitive RCT to advance 
this area of research.
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